<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02363725</url>
  </required_header>
  <id_info>
    <org_study_id>9439</org_study_id>
    <nct_id>NCT02363725</nct_id>
  </id_info>
  <brief_title>Interest of COLchicine in the Treatment of Patients With Acute Myocardial INfarction and With Inflammatory Response</brief_title>
  <acronym>COLIN</acronym>
  <official_title>Interest of COLchicine in the Treatment of Patients With Acute Myocardial INfarction and With Inflammatory Response</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Montpellier</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background:

      Colchicine is an old well-known venerable drug routinely used in gout attacks for instance.

      More recnetly it is regularly use in the treatment of pericarditis. It couls exert
      antiiflammatory effects targeting the adverse inflammation occuring incase of acute
      myocardial infarction, which is involved in poor outcomes or longer stay at hospital.

      Endpoints:

        -  Main endpoint: AUC CRP during the initial hospital stay

        -  Secondary endpoints:

             -  Clinical: oucomes

             -  Imaging: ETT, MRI

             -  Biological: various biomarkers

      Method Randomized, controled, open-labbelled, comparing two parallel arms: conventionnal
      optimal treatment versus conventionnal optimal treatment + colchicine
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Actual">August 2016</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC CRP</measure>
    <time_frame>5 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Drug tolerance</measure>
    <time_frame>1 year</time_frame>
    <description>Clinical outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hospitalization time</measure>
    <time_frame>1 year</time_frame>
    <description>Clinical outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CRP measurement</measure>
    <time_frame>1 year</time_frame>
    <description>Intrahospital peak CPK (Biological outcome)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CPK measurement</measure>
    <time_frame>1 year</time_frame>
    <description>Size IDM (pic and kinetics) (Biological outcome)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Troponin-hs measurement</measure>
    <time_frame>1 year</time_frame>
    <description>Size IDM (pic and kinetics) (Biological outcome)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Creatinine level</measure>
    <time_frame>Day of inclusion and one month after inclusion</time_frame>
    <description>Biological outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>measurement of left ventricular end-systolic volume</measure>
    <time_frame>Day of inclusion and one month after inclusion</time_frame>
    <description>Remodeling ETT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>measurement of left ventricular diastolic volume</measure>
    <time_frame>Day of inclusion and one month after inclusion</time_frame>
    <description>Remodeling ETT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>measurement remodeling</measure>
    <time_frame>One month after inclusion</time_frame>
    <description>Remodeling ETT</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Acute Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Conventionnal treatment</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Optimal conventional treatment used for patients admitted for STEMI (ESC guidelines 2012):
Double anti-aggregation
IEC (or sartan) at best tolerated dose
Beta-blocker at best tolerated dose
High dose statin (usually atorvastatin 80 mg daily)
If ventricular dysfunction; inhibitor minérolcorticoïdes (the eplerenone more often)
Any other treatment will be logged.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventionnal + Colchimax®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Optimal conventional treatment + Colchimax®</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Colchimax®</intervention_name>
    <arm_group_label>Conventionnal + Colchimax®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Conventional treatment</intervention_name>
    <arm_group_label>Conventionnal treatment</arm_group_label>
    <arm_group_label>Conventionnal + Colchimax®</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Acute myocardial inflarction (occlusion of coronary artery as assessed on the coronaro
             angiogram)

          -  Adult (18-90y)

          -  Men / women

          -  Aigned informed consent

          -  Health insurance

        Exclusion Criteria:

          -  Cardiogenic shock

          -  Digestive troubles

          -  Active bowels inflammatory disease (Crhon, chronic, diarrhea...)

          -  Intolerance to the drug

          -  Renal insufficiency clearance &lt; 30mL/min

          -  Immunosuppression, aplasia

          -  Active infectious disease, active known neoplasia, chronic inflammatory disease

          -  Hypersensitivity, allergy to one of studies components

          -  Active liver disease

          -  Poor hemodynamic conditions

          -  Recent severe sepsis

          -  Chronic treatment with corticoids or no steroids antiinflammatory agents

          -  No possibility for informed consent

          -  Protected by the law

          -  Poor abservance

          -  History of toxicomania, suicice attempts

          -  Pregnacy, breeding, project of pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francois ROUBILLE, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Montpellier France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Arnaud de Villeneuve</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 8, 2015</study_first_submitted>
  <study_first_submitted_qc>February 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 16, 2015</study_first_posted>
  <last_update_submitted>January 16, 2017</last_update_submitted>
  <last_update_submitted_qc>January 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute myocardial infarction</keyword>
  <keyword>Inflammation</keyword>
  <keyword>CRP</keyword>
  <keyword>Colchicine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colchicine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

